T-cell activation and proliferation pathways (NFAT signaling and nucleotide synthesis)

The target designation 'T cells – combined NFAT signaling and DNA/RNA synthesis' refers to a synergistic pharmacological strategy used to achieve profound immunosuppression by targeting two distinct phases of the T-cell life cycle. The first component, the Nuclear Factor of Activated T-cells (NFAT) signaling pathway, is the primary driver of cytokine gene expression (notably IL-2) following T-cell receptor engagement (Macian, F. Nature Reviews Immunology, 2005). The second component involves the metabolic pathways for DNA and RNA synthesis, which are upregulated to support the rapid clonal expansion of activated lymphocytes (Allison, A. C. Lupus, 2005). By combining calcineurin inhibitors, which block NFAT activation, with antimetabolites that disrupt nucleotide synthesis, clinicians can effectively halt both the initiation of the immune response and the subsequent proliferation of effector cells. This dual-target approach is the standard of care in solid organ transplantation and is frequently employed in the management of refractory autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (StatPearls, Calcineurin Inhibitors, 2023). However, this broad suppression of T-cell function carries significant risks, including increased susceptibility to opportunistic infections and a higher long-term incidence of malignancies.

Other names

NFAT signaling and nucleotide synthesis inhibitionCombined T-cell immunosuppression pathwaysT cells – combined NFAT signaling and DNA/RNA synthesis

Simultaneous inhibition of calcineurin-mediated NFAT dephosphorylation (blocking cytokine transcription) and inhibition of de novo purine or pyrimidine synthesis (blocking DNA/RNA replication required for proliferation).